Get the Stockscreener App
16.57
0.48%
-0.08
After Hours:
16.52
-0.05
-0.30%
Aurinia Pharmaceuticals Inc stock is traded at $16.57, with a volume of 686.26K.
It is down -0.48% in the last 24 hours and up +7.95% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$16.65
Open:
$16.57
24h Volume:
686.26K
Relative Volume:
0.48
Market Cap:
$2.20B
Revenue:
$298.30M
Net Income/Loss:
$298.21M
P/E Ratio:
7.6582
EPS:
2.1637
Net Cash Flow:
$166.93M
1W Performance:
+8.37%
1M Performance:
+7.95%
6M Performance:
+13.57%
1Y Performance:
+35.04%
1-Day Range:
$16.31
$16.68
1-Week Range:
$15.15
$17.80
52-Week Range:
$10.34
$19.25
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
16.57 | 2.30B | 298.30M | 298.21M | 166.93M | 2.1637 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Aurinia (NASDAQ: AUPH) officer to sell 47,000 shares for taxes - Stock Titan
Teva and Aurinia settle generics dispute over lupus drug, voclosporin - Life Sciences IP Review
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates - Eastern Progress
Zacks Investment ResearchGlobes - Globes - Israel Business News
Aurinia Secures Lupkynis Exclusivity Through 2036 in Teva Patent Settlement - finance.biggo.com
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises - Yahoo Finance UK
Bloom Burton Upgrades Aurinia Pharmaceuticals(AUPH.US) to Buy Rating, Raises Target Price to $21 - Moomoo
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Benzinga
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17 - Moomoo
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain - Yahoo Finance
Aurinia Pharmaceuticals and Teva Pharmaceuticals Resolve Patent Litigation Over Generic Voclosporin Capsules - Kalkine Media
AUPH Stock Rallies 6% After-Hours — Here’s Why - TradingView
Aurinia Settles Patent Lawsuit With Teva; Shares Rise After Hours - marketscreener.com
Aurinia, Teva Reach Voclosporin Patent Litigation Settlement - TipRanks
Aurinia stock falls on Teva patent settlement for voclosporin By Investing.com - Investing.com Canada
Aurinia stock falls on Teva patent settlement for voclosporin - Investing.com
Aurinia settles patent dispute with Teva over generic drug - Investing.com
Aurinia Settles Patent Litigation with Teva - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Aurinia Pharmaceuticals Inc (AUPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aurinia (AUPH) Latest Price Review: Rises 0.07% to $15.30 in the Current Update; Level Check: the Near-Term Reference Band Stretches From $14.54 to $16.07 under the Current SnapshotETF Outflow Streak - Vinanet
Aurinia (AUPH) Earnings Metrics: EPS Comes in Above Forecast in the Current Update; Trading-Day Reaction: Shares Move 0.07% UpQuarterly Profit Report - vinanet.vn
(AUPH) Risk Channels and Responsive Allocation - Stock Traders Daily
Aurinia Pharmaceuticals advances Lupkynis in ph... - Pluang
Aurinia Pharmaceuticals Doubles Down On Its Pipeline (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Navigating Growth in Biotech with a 10% Upside Potential - DirectorsTalk Interviews
Aurinia Pharmaceuticals (AUPH) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded by Wall Street Zen to Buy - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Strong Q2 Earnings And Reaffirmed 2026 Guidance - simplywall.st
Aurinia Pharmaceuticals Announces Q2 2026 Financial Results with Strong Revenue and Income Growth - Kalkine Media
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates - Yahoo Finance
Aurinia Pharmaceuticals Inc. 2026: Revenue $83.22M, EPS $0.28— 10-Q Summary - TradingView
AUPH: Strong revenue and profit growth fueled by LUPKYNIS sales and disciplined capital allocation - TradingView
Aurinia Pharmaceuticals posts Q2 revenue $83.2M, net income $37.4M; reiterates 2026 guidance - TradingView
Aurinia Q2 revenue rises 19 percent to $83.2 million - Quiver Quantitative
AUPH: Strong revenue and net income growth driven by LUPKYNIS, with robust 2026 outlook - TradingView
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress - marketscreener.com
Earnings Flash (AUPH) Aurinia Pharmaceuticals Inc. Reports Q2 Revenue $83.2M, Vs. FactSet Est of $80.4M - Moomoo
BRIEF-Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million - TradingView
(AUPH) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis: Uncovering a 16.68% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap Despite Its 50% Gain - simplywall.st
Lazard Asset Management LLC Sells 106,820 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharmaceuticals Inc Revenue Breakdown – NASDAQ:AUPH - TradingView
Healthcare of Ontario Pension Plan Trust Fund Makes New Investment in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharma earnings up next as growth momentum faces test By Investing.com - Investing.com UK
OMERS ADMINISTRATION Corp Takes Position in Aurinia Pharmaceuticals Inc $AUPH - marketbeat.com
AUPH Q2'26 Earnings: EPS estimate is 0.24 USD - TradingView
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):